A carregar...
Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma
Melanoma is the deadliest cutaneous cancer. Activating mutations in NRAS are found in 20% of melanomas. NRAS-mutant melanoma is more aggressive and, therefore, has poorer outcomes, compared to non-NRAS-mutant melanoma. Despite promising preclinical data, to date immune checkpoint inhibitors remain t...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8202735/ https://ncbi.nlm.nih.gov/pubmed/34135599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S278095 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|